All Stories

  1. Radiation protection and structural stability of fungal melanin polylactic acid biocomposites in low Earth orbit
  2. Cell wall melanin impedes growth of the Cryptococcus neoformans polysaccharide capsule by sequestering calcium
  3. The structure of a C. neoformans polysaccharide motif recognized by protective antibodies: A combined NMR and MD study
  4. The hypothermic nature of fungi
  5. Similar evolutionary trajectories in an environmental Cryptococcus neoformans isolate after human and murine infection
  6. Bet-hedging antimicrobial strategies in macrophage phagosome acidification drive the dynamics of Cryptococcus neoformans intracellular escape mechanisms
  7. On the relationship between Pathogenic Potential and Infective Inoculum
  8. Glyphosate inhibits melanization and increases susceptibility to infection in insects
  9. A glycan FRET assay for detection and characterization of catalytic antibodies to the Cryptococcus neoformans capsule
  10. Updating the fungal infection-mammalian selection hypothesis at the end of the Cretaceous Period
  11. The intracellular pathogen concept
  12. The Buoyancy ofCryptococcus neoformansIs Affected by Capsule Size
  13. The Capsule of Cryptococcus neoformans Modulates Phagosomal pH through Its Acid-Base Properties
  14. In Fungal Intracellular Pathogenesis, Form Determines Fate
  15. Opsonin-free, real-time imaging of Cryptococcus neoformans capsule during budding
  16. Analysis and Correction of Inappropriate Image Duplication: the Molecular and Cellular Biology Experience
  17. Extracellular vesicles and vesicle-free secretome of the protozoa Acanthamoeba castellanii under homeostasis and nutritional stress and their damaging potential to host cells
  18. Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species
  19. Using Preprints for Journal Clubs
  20. The Capsule of Cryptococcus neoformans
  21. Graduate Biomedical Science Education Needs a New Philosophy
  22. Erratum for Schloss et al., “Support Science by Publishing in Scientific Society Journals”
  23. What Is a Host? Attributes of Individual Susceptibility
  24. Support Science by Publishing in Scientific Society Journals
  25. Antibody-Mediated Catalysis in Infection and Immunity
  26. The mBio American Academy of Microbiology Submission Track in 2017
  27. Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility
  28. Rigorous Science: a How-To Guide
  29. A Framework for Improving the Quality of Research in the Biological Sciences
  30. Moonshot Science—Risks and Benefits
  31. Reply to “Funding by Lottery: Political Problems and Research Opportunities”
  32. ASM Journals Eliminate Impact Factor Information from Journal Websites
  33. ASM Journals Eliminate Impact Factor Information from Journal Websites
  34. ASM Journals Eliminate Impact Factor Information from Journal Websites
  35. ASM Journals Eliminate Impact Factor Information from Journal Websites
  36. ASM Journals Eliminate Impact Factor Information from Journal Websites
  37. ASM Journals Eliminate Impact Factor Information from Journal Websites
  38. ASM Journals Eliminate Impact Factor Information from Journal Websites
  39. ASM Journals Eliminate Impact Factor Information from Journal Websites
  40. The Holobiont/Hologenome Concept Series
  41. Revolutionary Science
  42. Impacted Science: Impact Is Not Importance
  43. (A)Historical Science
  44. Field Science—the Nature and Utility of Scientific Fields
  45. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
  46. The Justification for the Academy Track in mBio
  47. Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research
  48. Role of Cln1 during melanization of Cryptococcus neoformans
  49. Dual-Use Research of Concern (DURC) Review at American Society for Microbiology Journals
  50. Achieving Speaker Gender Equity at the American Society for Microbiology General Meeting
  51. Biofilm Formation by Cryptococcus neoformans
  52. Competitive Science: Is Competition Ruining Science?
  53. Lipid Biosynthetic Genes Affect Candida albicans Extracellular Vesicle Morphology, Cargo, and Immunostimulatory Properties
  54. Lymphatic Aging
  55. The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases
  56. A New Synthesis for Dual Use Research of Concern
  57. Solid-state NMR Reveals the Carbon-based Molecular Architecture of Cryptococcus neoformans Fungal Eumelanins in the Cell Wall
  58. Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences
  59. The Importance of Virology at a Time of Great Need and Great Jeopardy
  60. Distribution and impact of yeast thermal tolerance permissive for mammalian infection
  61. Release of mycobacterial antigens
  62. B cells and antibodies in the defense againstMycobacterium tuberculosisinfection
  63. Competitive Science: Is Competition Ruining Science?
  64. Radiolabeled Antibodies for Therapy of Infectious Diseases
  65. What is infectiveness and how is it involved in infection and immunity?
  66. mBio Addresses the Pause in Gain-of-Function (GOF) Experiments Involving Pathogens with Pandemic Potential (PPP)
  67. Falling down the Rabbit Hole: aTRIP Toward Lexiconic Precision in the “Gain-of-Function” Debate
  68. Vagueness and Costs of the Pause on Gain-of-Function (GOF) Experiments on Pathogens with Pandemic Potential, Including Influenza Virus
  69. Microbiology: Ditch the term pathogen
  70. Challenges posed by extracellular vesicles from eukaryotic microbes
  71. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection
  72. Compositional and immunobiological analyses of extracellular vesicles released byCandida albicans
  73. What Is a Host? Incorporating the Microbiota into the Damage-Response Framework: TABLE 1
  74. Acknowledgment of Invited Editors
  75. Functional Improvement of Regulatory T Cells from Rheumatoid Arthritis Subjects Induced by Capsular Polysaccharide Glucuronoxylomannogalactan
  76. Visualizing Non-lytic Exocytosis of Cryptococcus neoformans from Macrophages Using Digital Light Microscopy
  77. Financial costs and personal consequences of research misconduct resulting in retracted publications
  78. Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae
  79. A Role for LHC1 in Higher Order Structure and Complement Binding of the Cryptococcus neoformans Capsule
  80. Pathogenicity of Cryptococcus neoformans: an Evolutionary Perspective
  81. Pigment Production on L-Tryptophan Medium by Cryptococcus gattii and Cryptococcus neoformans
  82. Cryptococcus neoformans: Latency and Disease
  83. The History of Cryptococcus and Cryptococcosis
  84. Cryptococcosis
  85. Acquired Humoral Immunity to Cryptococcus neoformans
  86. Acquired Immunity against Fungi
  87. Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma
  88. Melanin: Structure, Function, and Biosynthesis in Cryptococcus
  89. The Architecture and Antigenic Composition of the Polysaccharide Capsule
  90. Cryptococcus neoformans: Nonvertebrate Hosts and the Emergence of Virulence
  91. Acquired Antibody-Mediated Immunity to Fungi
  92. Specialized Science
  93. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct
  94. Platelet-activating Factor Contributes to Bacillus anthracis Lethal Toxin-associated Damage
  95. The Intracellular Life ofCryptococcus neoformans
  96. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity
  97. Demonstration of a common indole-based aromatic core in natural and synthetic eumelanins by solid-state NMR
  98. The Tools for Virulence of Cryptococcus neoformans
  99. Isolation and identification of membrane vesicle-associated proteins in Gram-positive bacteria and mycobacteria
  100. Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis
  101. Global structures of IgG isotypes expressing identical variable regions
  102. The constant region affects antigen binding of antibodies to DNA by altering secondary structure
  103. Binding of the wheat germ lectin to Cryptococcus neoformans chitooligomers affects multiple mechanisms required for fungal pathogenesis
  104. Phylogenetics and Evolution of Virulence in the Kingdom Fungi
  105. Radioimmunotherapy ofCryptococcus neoformansspares bystander mammalian cells
  106. Progress in understanding fungal pathogenesis
  107. Correction: Why Has the Number of Scientific Retractions Increased?
  108. Why Has the Number of Scientific Retractions Increased?
  109. Immunogenicity of mycobacterial vesicles in humans: Identification of a new tuberculosis antibody biomarker
  110. The Role of Host Gender in the Pathogenesis of Cryptococcus neoformans Infections
  111. Why We Cheat
  112. Allergen1regulates polysaccharide structure inCryptococcus neoformans
  113. Disease-Enhancing Antibodies Improve the Efficacy of Bacterial Toxin-Neutralizing Antibodies
  114. Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma
  115. Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development
  116. Exserohilum rostratum fungal meningitis associated with methylprednisolone injections
  117. Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy
  118. The Microbial Capsular Polysaccharide Galactoxylomannan Inhibits IL-17A Production in Circulating T Cells from Rheumatoid Arthritis Patients
  119. Elucidating the Structural Framework of Synthetic and Fungal Melanins by Solid-State NMR
  120. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies
  121. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan
  122. Compton Scattering by Internal Shields Based on Melanin-Containing Mushrooms Provides Protection of Gastrointestinal Tract from Ionizing Radiation
  123. Fungi and the Rise of Mammals
  124. Using Solid-State NMR To Monitor the Molecular Consequences of Cryptococcus neoformans Melanization with Different Catecholamine Precursors
  125. Recent progress in vaccines against fungal diseases
  126. Winner Takes All
  127. Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype
  128. Quorum sensing in fungi – a review
  129. Immunoglobulins in Defense, Pathogenesis, and Therapy of Fungal Diseases
  130. Mouse models for the study of fungal pneumonia
  131. The future of biological warfare
  132. Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
  133. Strain-related differences in antibody-mediated changes in gene expression are associated with differences in capsule and location of binding
  134. Serum albumin disrupts Cryptococcus neoformans and Bacillus anthracis extracellular vesicles
  135. Fungal Melanins Differ in Planar Stacking Distances
  136. Adaptations of avian flu virus are a cause for concern
  137. Capsules from Pathogenic and Non-Pathogenic Cryptococcus spp. Manifest Significant Differences in Structure and Ability to Protect against Phagocytic Cells
  138. Reforming Science
  139. A Global Forum for Clinical Microbiologists and Immunologists
  140. Q&A: What is a pathogen? A question that begs the point
  141. Recent Advances on Model Hosts
  142. Probing the Molecular Architecture and Assembly of Synthetic and Fungal Melanins with Solid-State NMR
  143. In Vitro Measurement of Phagocytosis and Killing of Cryptococcus neoformans by Macrophages
  144. Reforming Science: Structural Reforms
  145. A new synthesis for antibody-mediated immunity
  146. Synthesis and assembly of fungal melanin
  147. Vesicular transport systems in fungi
  148. Protection of the Melanized Fungus Cryptococcus Neoformans From Lethal Dose Gamma Irradiation Involves Changes in Melanin's Chemical Structure and Paramagnetic Properties
  149. Methylxanthine Inhibit Fungal Chitinases and Exhibit Antifungal Activity
  150. Amoeba Provide Insight into the Origin of Virulence in Pathogenic Fungi
  151. Ten Challenges on Cryptococcus and Cryptococcosis
  152. Protection of Melanized Cryptococcus neoformans from Lethal Dose Gamma Irradiation Involves Changes in Melanin's Chemical Structure and Paramagnetism
  153. Cryptococcus neoformans Capsular Enlargement and Cellular Gigantism during Galleria mellonella Infection
  154. Gamma radiation interacts with melanin to alter its oxidation–reduction potential and results in electric current production
  155. Cryptococcus neoformansgalactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy
  156. Microbial Virulence as an Emergent Property: Consequences and Opportunities
  157. The effect of L-DOPA onCryptococcus neoformansgrowth and gene expression
  158. Phospholipids Trigger Cryptococcus neoformans Capsular Enlargement during Interactions with Amoebae and Macrophages
  159. Role for Golgi reassembly and stacking protein (GRASP) in polysaccharide secretion and fungal virulence
  160. mBio’s First Birthday
  161. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice
  162. Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis
  163. Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity
  164. Melanin and Resistance to Ionizing Radiation in Fungi
  165. Fungal Polysaccharides: Biological Activity Beyond the Usual Structural Properties
  166. Biophysical Methods for the Study of Microbial Surfaces
  167. Phenylalanine hydroxylase (PAH) from the lower eukaryote Leishmania major
  168. Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
  169. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line
  170. Melanin-Covered Nanoparticles for Protection of Bone Marrow During Radiation Therapy of Cancer
  171. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6
  172. Cryptococcus
  173. Biogenesis of extracellular vesicles in yeast
  174. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule ofCryptococcus neoformans
  175. Reproducible Science
  176. Role of CD45 Signaling Pathway in Galactoxylomannan-Induced T Cell Damage
  177. An insight into the antifungal pipeline: selected new molecules and beyond
  178. Radioimmunotherapy Is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection
  179. Paramecium species ingest and kill the cells of the human pathogenic fungus Cryptococcus neoformans
  180. Proteasome Inhibitors Prevent Caspase-1-Mediated Disease in Rodents Challenged with Anthrax Lethal Toxin
  181. Intracellular cryptococci suppress Fc-mediated cyclin D1 elevation
  182. Correction: Fungal Cell Gigantism during Mammalian Infection
  183. Fungal Cell Gigantism during Mammalian Infection
  184. Characterization of Yeast Extracellular Vesicles: Evidence for the Participation of Different Pathways of Cellular Traffic in Vesicle Biogenesis
  185. Destruction of Microbial Collections in Response to Select Agent and Toxin List Regulations
  186. ASM Launches mBio
  187. Cryptococci at the brain gate: break and enter or use a Trojan horse?
  188. Abstract 5344: The contribution of unlabeled antibodies to intracellular antigens to efficacy of radioimmunotherapy in experimental metastatic melanoma and cervical cancer
  189. Circular Dichroism reveals evidence of coupling between immunoglobulin constant and variable region secondary structure☆
  190. Hark back: Passive immunotherapy for influenza and other serious infections
  191. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism
  192. The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of 188Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice
  193. The use of chitosan to damage Cryptococcus neoformans biofilms
  194. Microbial threat lists: obstacles in the quest for biosecurity?
  195. Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo
  196. Natural Melanin Produced in Fungi Protects Cells from High Dose Ionizing Radiation: An EPR Study
  197. Monoclonal antibody-based therapies for microbial diseases
  198. The still obscure attributes of cryptococcal glucuronoxylomannan
  199. Cryptococcus neoformans cryoultramicrotomy and vesicle fractionation reveals an intimate association between membrane lipids and glucuronoxylomannan
  200. Vertebrate Endothermy Restricts Most Fungi as Potential Pathogens
  201. Physico-Chemical Evaluation of Rationally Designed Melanins as Novel Nature-Inspired Radioprotectors
  202. The “Nuclearization” of Biology Is a Threat to Health and Security
  203. The Elastic Properties of the Cryptococcus neoformans Capsule
  204. Virulence factors and their mechanisms of action: the view from a damage–response framework
  205. Resistance of melanized yeast cells of Paracoccidioides brasiliensis to antimicrobial oxidants and inhibition of phagocytosis using carbohydrates and monoclonal antibody to CD18
  206. The case for pathogen-specific therapy
  207. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies
  208. Structural and functional properties of the Trichosporon asahii glucuronoxylomannan
  209. Vesicular transport across the fungal cell wall
  210. Radioimmunotherapy of Infectious Diseases
  211. Sec6-dependent sorting of fungal extracellular exosomes and laccase ofCryptococcus neoformans
  212. Is Peer Review Censorship?
  213. The still obscure attributes of cryptococcal glucuronoxylomannan
  214. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes
  215. Chapter 4 The Capsule of the Fungal Pathogen Cryptococcus neoformans
  216. Intracellular pathogenic bacteria and fungi — a case of convergent evolution?
  217. Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin
  218. Biodefense Research: A Win-Win Challenge
  219. Evolution of Intracellular Pathogens
  220. Capsule enlargement inCryptococcus neoformansconfers resistance to oxidative stress suggesting a mechanism for intracellular survival
  221. In vitro evaluation, biodistribution and scintigraphic imaging in mice of radiolabeled anthrax toxins
  222. The Outcome of Phagocytic Cell Division with Infectious Cargo Depends on Single Phagosome Formation
  223. Fungal killing by mammalian phagocytic cells
  224. Antibody action after phagocytosis promotesCryptococcus neoformansandCryptococcus gattiimacrophage exocytosis with biofilm-like microcolony formation
  225. Vesicular transport inHistoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes
  226. A role for vesicular transport of macromolecules across cell walls in fungal pathogenesis
  227. Finite-Element Model of Interaction between Fungal Polysaccharide and Monoclonal Antibody in the Capsule of Cryptococcus neoformans
  228. Characterization of Phenotypic Switching in Cryptococcus neoformans Biofilms
  229. Following Fungal Melanin Biosynthesis with Solid-State NMR: Biopolymer Molecular Structures and Possible Connections to Cell-Wall Polysaccharides †
  230. Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins
  231. The immunoglobulin constant region contributes to affinity and specificity
  232. Analysis of epitope information related toBacillus anthracisandClostridium botulinum
  233. Passive administration of monoclonal antibodies to Anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis
  234. Pulmonary cryptococcosis induces chitinase in the rat
  235. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1
  236. The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement
  237. Exchanging Murine and Human Immunoglobulin Constant Chains Affects the Kinetics and Thermodynamics of Antigen Binding and Chimeric Antibody Autoreactivity
  238. Determinants of virulence in the pathogenic fungi
  239. New insights on the pathogenesis of invasive Cryptococcus neoformans infection
  240. Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51
  241. Phage Display Library Derived Peptides that Bind to Human Tumor Melanin as Potential Vehicles for Targeted Radionuclide Therapy of Metastatic Melanoma
  242. Treating Cancer as an Infectious Disease—Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral Etiology
  243. Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations
  244. Caspofungin reduces the incidence of fungal contamination in cell culture
  245. Fungal Infections (In Humans)
  246. Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches
  247. Targeting the Virus with Radioimmunotherapy in Virus-Associated Cancers
  248. Coccidioides posadasii produces melanin in vitro and during infection
  249. SEROLOGIC EVIDENCE FOR REGIONAL DIFFERENCES IN PEDIATRIC CRYPTOCOCCAL INFECTION
  250. Ionizing Radiation Changes the Electronic Properties of Melanin and Enhances the Growth of Melanized Fungi
  251. Targeting host cells harbouring viruses with radiolabeled antibodies
  252. The volume and hydration of the Cryptococcus neoformans polysaccharide capsule
  253. Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar
  254. Pathogenesis of Cryptococcus neoformans
  255. Exploiting Amoeboid and Non-Vertebrate Animal Model Systems to Study the Virulence of Human Pathogenic Fungi
  256. Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages
  257. DEVELOPING A MATHEMATICAL MODEL OF PHAGOCYTOSIS: A LEARNING PROCESS
  258. Update : Renaissance of Targeting Molecules for Melanoma
  259. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance
  260. Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins
  261. Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages
  262. The capsular dynamics of Cryptococcus neoformans
  263. Characterization of a flocculation-like phenotype in Cryptococcus neoformans and its effects on pathogenesis
  264. Immunomodulators as an antimicrobial tool
  265. Efficacy of voriconazole in experimental Cryptococcus neoformans infection
  266. Specific Antibody to Cryptococcus neoformans Glucurunoxylomannan Antagonizes Antifungal Drug Action against Cryptococcal Biofilms In Vitro
  267. Equatorial ring-like channels in the Cryptococcus neoformans polysaccharide capsule
  268. Interaction of Radiolabeled Antibodies with Fungal Cells and Components of the Immune System In Vitro and during Radioimmunotherapy for Experimental Fungal Infection
  269. Enhanced Allergic Inflammation and Airway Responsiveness in Rats with Chronic Cryptococcus neoformans Infection: Potential Role for Fungal Pulmonary Infection in the Pathogenesis of Asthma
  270. Radiolabeled Melanin-Binding Peptides Are Safe and Effective in Treatment of Human Pigmented Melanoma in a Mouse Model of Disease
  271. Structural and functional characterization of glycosylation in an immunoglobulin G1 to Cryptococcus neoformans glucuronoxylomannan
  272. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8
  273. Melanization affects susceptibility of Cryptococcus neoformans to heat and cold1
  274. The weapon potential of human pathogenic fungi
  275. Polysaccharide-containing conjugate vaccines for fungal diseases
  276. A Reappraisal of Humoral Immunity Based on Mechanisms of Antibody‐Mediated Protection Against Intracellular Pathogens
  277. The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding
  278. Melanin in the dimorphic fungal pathogen Paracoccidioides brasiliensis: effects on phagocytosis, intracellular resistance and drug susceptibility
  279. Comparative analysis of Cryptococcus neoformans acid-resistant particles generated from pigmented cells grown in different laccase substrates
  280. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
  281. The potential of antibody-mediated immunity in the defence against biological weapons
  282. Melanin as a potential target for radionuclide therapy of metastatic melanoma
  283. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures
  284. A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity
  285. Prof. Dr. Ricardo Arturo Ronderos (1928-1995)
  286. Microstructure of Cell Wall-Associated Melanin in the Human Pathogenic Fungus Cryptococcus neoformans †
  287. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection?
  288. Investigation of Fungal Deterioration of Synthetic Paint Binders Using Vibrational Spectroscopic Techniques
  289. Coping with Multiple Virulence Factors: Which Is Most Important?
  290. Role of Antibody-Mediated Immunity in Host Defense against Mycobacterium tuberculosis
  291. Prospects of vaccines for medically important fungi Feasibility and prospects for a vaccine to prevent cryptococcosis
  292. Glucuronoxylomannan, a Microbial Compound, Regulates Expression of Costimulatory Molecules and Production of Cytokines in Macrophages
  293. Blastomyces dermatitidis produces melanin in vitro and during infection
  294. Passive antibody therapy for infectious diseases
  295. The methodology for determining the efficacy of antibody-mediated immunity
  296. The weapon potential of a microbe
  297. Response to Fehr and Ochsenbein: ‘Good’, ‘bad’ and ‘neutral’ antibodies depend on the host–microbe interaction
  298. Experimental modulation of capsule size in Cryptococcus neoformans
  299. Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth
  300. Serotype distribution of Cryptococcus neoformans in patients in a tertiary care center in India1
  301. A ten-year-old boy with a pulmonary nodule secondary to Cryptococcus neoformans: case report and review of the literature
  302. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
  303. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
  304. The damage-response framework of microbial pathogenesis
  305. ‘Anti-virulence’ genes – further muddling the lexicon?
  306. Antibody-mediated regulation of cellular immunity and the inflammatory response
  307. Phenotypic switching of Cryptococcus neoformans can influence the outcome of the human immune response
  308. ‘Ready made’ virulence and ‘dual use’ virulence factors in pathogenic environmental fungi — the Cryptococcus neoformans paradigm
  309. Unlocking the Molecular Structure of Fungal Melanin Using 13 C Biosynthetic Labeling and Solid-State NMR †
  310. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirectC3-mediated interactions
  311. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans
  312. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis
  313. Microbial virulence results from the interaction between host and microorganism
  314. The contribution of melanin to microbial pathogenesis
  315. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils
  316. Site-specific characterization of the N-linked oligosaccharides of a murine immunoglobulin M by high-performance liquid chromatography/electrospray mass spectrometry
  317. Cryptococcosis
  318. Phenotypic switching in Cryptococcus neoformans
  319. The meaning of microbial exposure, infection, colonisation, and disease in clinical practice
  320. Passive Antibody Administration (Immediate Immunity) as a Specific Defense Against Biological Weapons
  321. Induced humoral immunity and vaccination against major human fungal pathogens
  322. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) Are Involved in Complement-Independent Antibody-Mediated Phagocytosis of Cryptococcus neoformans
  323. Antibody to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated by antigen-presenting cells
  324. Antibodies for defense against biological attack
  325. Identification and characterization of the Cryptococcus neoformans phosphomannose isomerase-encoding gene, MAN1, and its impact on pathogenicity
  326. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection
  327. Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection
  328. Adjunctive Immune Therapy for Fungal Infections
  329. Cryptococcus neoformans: intracellular or extracellular?
  330. Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection
  331. Host‐Pathogen Interactions: The Attributes of Virulence
  332. Intracellular parasitism of macrophages by Cryptococcus neoformans
  333. Immunity to Fungi
  334. Fungal Infections in Humans
  335. Glyphosate Inhibits Melanization of Cryptococcus neoformans and Prolongs Survival of Mice after Systemic Infection
  336. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans
  337. The Effect of the Echinocandin Analogue Caspofungin on Cell Wall Glucan Synthesis by Cryptococcus neoformans
  338. Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy
  339. Human and murine immunoglobulin expression vector cassettes
  340. Isolation and serological analyses of fungal melanins
  341. Host–microbe interactions: fungi
  342. Melanin and virulence in Cryptococcus neoformans
  343. Melanisation of Cryptococcus neoformans in human brain tissue
  344. Neutrophils from Patients with Advanced Human Immunodeficiency Virus Infection Have Impaired Complement Receptor Function and Preserved Fcγ Receptor Function
  345. Passive Antibody Therapies: Progress and Continuing Challenges
  346. Cryptococcus neoformans by Casadevall, Arturo & Perfect, John R. (1998) ASM Press, Washington, DC. Hardcover. 542 pp. $89.95. (ASM Member price: $79.95).
  347. Monoclonal Antibody–Mediated Toxicity in Cryptococcus neoformans Infection: Mechanism and Relationship to Antibody Isotype
  348. Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells
  349. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans
  350. Separated at Birth
  351. Serial Isolates of Cryptococcus neoformans from Patients with AIDS Differ in Virulence for Mice
  352. Cryptococcus neoformans
  353. Effect of Antibody to Capsular Polysaccharide on Eosinophilic Pneumonia in Murine Infection with Cryptococcus neoformans
  354. Effect of Immune Mechanisms on the Pharmacokinetics and Organ Distribution of Cryptococcal Polysaccharide
  355. Response from Casadevall
  356. Antibody-mediated protection against intracellular pathogens
  357. Antibody-based therapies as anti-infective agents
  358. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes
  359. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes
  360. The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes
  361. Reply
  362. PERSISTENT VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM BACTEREMIA
  363. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy
  364. Antibody-Based Therapies for Emerging Infectious Diseases
  365. Cryptococcus neoformans: Paradigm for the Role of Antibody Immunity Against Fungi?
  366. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications
  367. Reply
  368. Reply
  369. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro
  370. Antibody immunity and Cryptococcus neoformans
  371. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody
  372. Decreased Fluconazole Susceptibility of a Relapse Cryptococcus neoformans Isolate After Fluconazole Treatment
  373. Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans
  374. Cryptococcus neoformans infection can elicit protective antibodies in mice
  375. Enhancement of HIV Type 1 Infectivity in Vitro by Capsular Polysaccharide of Cryptococcus neoformans and Haemophilus influenzae
  376. Reactive Nitrogen Intermediates in Human Neuropathology: An Overview
  377. The Presence of Cryptococcal Capsular Polysaccharide Increases the Sensitivity of HIV-1 Coculture in Children
  378. MU switch region deletion is associated with both T cell independent and T cell dependent responses
  379. The reply
  380. Monoclonal antibody based ELISAs for cryptococcal polysaccharide
  381. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS
  382. URA5 gene of Cryptococcus neoformans var. gattii: evidence for a close phylogenetic relationship between C. neoformans var. gattii and C. neoformans var. neoformans.
  383. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans
  384. Thermal difference circular dichroism of Pf1 filamentous virus and effects of mercury(II), silver(I), and copper(II)
  385. Raman spectroscopy of mercury(II) binding to two filamentous viruses: Ff (fd, M13, f1) and Pf1
  386. The precursor complex of Pf3 bacteriophage
  387. Silver and mercury probing of deoxyribonucleic acid structures in the filamentous viruses fd, If1, IKe, Xf, Pf1, and Pf3
  388. DNA packing in the filamentous viruses fd, Xf, Pfl and Pf3
  389. Notes and Queries
  390. Immunotherapy for Fungal Infections
  391. Antibody-Mediated Immunity to Fungi in the Lungs
  392. Carbohydrate-Based Antifungal Vaccines
  393. The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases